Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma

Anticancer Research

Volumn 25, Issue 6 A, 2005, Pages 3715-3723

  Yamamoto, Masaaki ^a   Iwaasa, Mitsutoshi ^a   Nonaka, Masani ^a   Tsugu, Hitoshi ^a   Nabeshima, Kazuki ^a   Fukushima, Takeo ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaplastic oligodendroglioma; Procarbazine; Ranimustine; Vincristine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; ETOPOSIDE; PROCARBAZINE; RANIMUSTINE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RADIATION DOSE; RISK REDUCTION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN MANIFESTATION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; OLIGODENDROGLIOMA; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 27844472887     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Bauman GS and Cairncross JG: Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas. Semin Radiat Oncol 11: 170-180, 2001.
2. Lindegaard KF, Mork SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, Dahl O and Ganz J: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67: 224-230, 1987.
3. Mork SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, Harvei S and Ganz J: Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63: 881-889, 1985.
4. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD and Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76: 428-434, 1992.
5. Soffietti R: Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin Pharmacother 5: 295-306, 2004.
6. Ellis TL, Stieber VW and Austin RC: Oligodendroglioma. Curr Treat Options Oncol 4: 479-490, 2003.
7. Cairncross JG, Macdonald DR and Ramsay DA: Aggressive Oligodendroglioma: a chemosensitive tumor. Neurosurgery 31: 78-82, 1992.
8. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D and Rattner B: The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741-745, 1992.
9. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr et al: Chemotherapy for anaplastic Oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013-2021, 1994.
10. Kim L, Hochberg FH, Thornton AF, Harsh GRT, Patel H, Finkelstein D and Louis DN: Procarbazine, lomustine and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85: 602-607, 1996.
11. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD and von Deimling A: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of Oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54: 91-95, 1995.
12. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA and Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90: 1473-1479, 1998.
13. Jeuken JW, Sprenger SH, Wesseling P, Macville MV, von Deimling A, Teepen HL, van Overbeeke JJ and Boerman RH: Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol 58: 606-612, 1999.
14. Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, Iuzzolino P, Gardiman M, Talacchi A and Ermani M: Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A phase II study. Cancer 101: 2079-2085, 2004.
15. Paleologos NA and Cairncross JG: Treatment of oligodendroglioma: an update. Neuro-oncol 1: 61-68, 1999.
16. van den Bent MJ: Diagnosis and management of oligodendroglioma. Semin Oncol 31: 645-652, 2004.
17. Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D and Cairncross G: Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15: 1294-1301, 1997.
18. Celli P, Nofrone I, Palma L, Cantore G and Fortuna A: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35: 1018-1034, discussion 1034-1015, 1994.
19. Gannett DE, Wisbeck WM, Silbergeld DL and Berger MS: The role of postoperative irradiation in the treatment of oligodendroglioma. Int J Radiat Oncol Biol Phys 30: 567-573, 1994.
20. Chinot O: Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28: 13-18, 2001.
21. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D and Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95: 190-198, 2001.
22. Bucci MK, Maity A, Janss AJ, Belasco JB, Fisher MJ, Tochner ZA, Rorke L, Sutton LN, Phillips PC and Shu HK: Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer 101: 817-824, 2004.
23. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R and Kyritsis AP: Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65: 259-266, 2003.
24. Yamamoto M, Ueno Y, Hayashi S and Fukushima T: The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors. Anticancer Res 22: 4265-4268, 2002.
25. Kleihues P, Burger PC and Scheithauer BW (eds.): Histological Typing of Tumors of the Central Nervous System. 2nd ed., Berlin: Springer-Verlag, pp. 11-20, 1993.
26. Miller AB, Hoogstraten B, Staquent M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
27. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE and Bigner DD: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155: 375-386, 1999.
28. Jenkins RB, Curran W, Scott CB and Cairncross G: Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol 24: 506-508, 2001.
29. Soffietti R, Ruda R, Bradac GB and Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43: 1066-1073, 1998.
30. Buckner JC, Gesme D Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG and Jenkins R: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21: 251-255, 2003.
31. Kristof RA, Neuloh G, Hans V, Deckert M, Urbach H, Schlegel U, Simon M and Schramm J: Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III. J Neurooncol 59: 231-237, 2002.
32. Hussein MR and Baidas S: Advances in diagnosis and management of oligodendroglioma. Expert Rev Anticancer Ther 2: 520-528, 2002.
33. Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KM and Berg KD: Molecular diagnosis of oligodendroglioma in paraffin sections. Lab Invest 83: 419-428, 2003.
34. Brandes AA, Basso U, Vastola F, Tosoni A, Pasetto LM, Jirillo A, Lonardi S, Paris MK, Koussis H, Monfardini S and Ermani M: Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol 14: 1727-1731, 2003.
35. Peterson K, Paleologos N, Forsyth P, Macdonald DR and Cairncross JG: Salvage chemotherapy for oligodendroglioma. J Neurosurg 85: 597-601, 1996.
36. Soffietti R, Nobile M, Ruda R, Borgognone M, Costanza A, Laguzzi E and Mutani R: Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer 100: 807-813, 2004.
37. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S and Prados M: Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21: 2305-2311, 2003.
38. van den Bent MJ, Chinot O, Boogerd W, Bravo Marques J, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N and Baron B: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14: 599-602, 2003.
39. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000.
40. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH and Zaknoen SL: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 4: 261-267, 2002.
41. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA and Abrey LE: A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol 4: 39-43, 2002.
42. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO and Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002.
43. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht Ch J, Allgeier A and Gorlia T: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21: 2525-2528, 2003.
44. van den Bent MJ: Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol 17: 675-680, 2004.